



Organisation
of European
Cancer Institutes

In collaboration with



Oncology Days



**WORKING TOGETHER TO IMPROVE
QUALITY AND REDUCE INEQUALITIES**

HELSINKI 2024

**GENERAL ASSEMBLY AND
SCIENTIFIC CONFERENCES**

12 - 14 June 2024

Hotel Presidentti, Helsinki, Finland



**FINAL
PROGRAMME**

The OECI Oncology Days are a focal point for the European cancer community, where leaders, scientists, clinicians, and other healthcare professionals gather to share the latest advances in cancer care and research. From cancer science to quality in comprehensive cancer care, patient empowerment and EC actions, we strive to put the spotlight on the hot topics, and highlight the excellence of our member institutions.

The OECI Oncology Days bring together representatives of our Members, who share with us the same challenge: placing patients at the centre of their cancer journey and working to provide them equal access to high quality cancer care and to the best available treatments. We try to achieve this together by strategic alliances in Europe and outside the continent. Several centres from Vietnam, Tanzania, Lebanon, Jordan, Turkey, Colombia and Chile, joined OECI, because they believe in the importance of exchanging with – and learning from – European models of excellence.

With 46 years of history since our foundation, we understood that the keys to achieving this vision are openness to experience, curiosity and dialogue. The OECI Oncology Days are a forum for dynamic exchange, creative thinking and cooperation - a space to focus on identifying key priorities and developing new solutions.

We are grateful to the Helsinki Comprehensive Cancer Centre who hosts the 46th Edition of our Members' Assembly of Directors.

This year's Edition will kickstart on June 12 with a session focusing on the OECI A&D Programme, which is currently comprising 60% of our 141 Members. A significant milestone has been achieved in 2023 as we have certified our first extra-European cancer centre in Chile – Fundación Arturo López Pérez (FALP). In addition, a new set of standards - the OECI European Quality Standards for Cancer Networks, have been piloted this year for the 2nd time in the Oncology Network South-East Netherlands (OncoZON), and a revision of all our standards is underway.

The path that led us to OECI46 is also the result of the contributions coming from our Working Groups and our members' active involvement in our agenda, paired with a precise and effective management. Namely, the activities developed within the Cancer Economics WG, the Biobanks and Pathobiology WG and the Outcomes Cancer Research WG. The activities carried out in these WGs fostered cancer-related EC projects.

The past years have brought to light a growing body of evidence on the benefits of shared decision-making with our patients. We have learnt that it is essential for health care professionals to move away from 'top-down' approaches and proactively co-design with patients the decisions related to their cancer journey. This is an important step forward, and the reason why OECI is relaunching its Patients' WG, that will be presenting in Helsinki its new Programme of Activities within the framework of the event.

Our mission to build a close-knit community aligns with Europe's Beating Cancer Plan and the actions launched by the EU Cancer Mission. The Programmes aim to ensure that by 2030, 90% of all patients should have access to National Comprehensive Cancer Centres linked through a EU Network.

Under the coordination of OECI, a large network of 27 Member States and 5 Associated Countries, a new Coordination and Support Action (CSA) – Comprehensive Cancer Networks

for Europe (CCI4EU), was launched on 1 May 2023. CCI4EU is a capacity building programme designed to rethink the cancer culture and reduce inequalities. The CSA involves 54 cancer centres, most of which are an OECI Member. Together with National Health Authorities, the cancer centres will contribute to creating or improving National Cancer Infrastructures. CCI4EU aims to drive change and improvement in research and care, and achieve greater integration between them with the support of an educational programme that should become a continuing educational initiative in each country.

As part of the OECI Scientific Conference 2024, a dynamic Session on the most relevant Joint Actions will take place. The Joint Actions leaders will be invited to present the state of play of their actions and find solutions to better integrate their efforts in order to benefit our patients, reduce political conflicts and avoid that national interests prevail over the objectives of our actions.

Helsinki 2024 is a turning point in the history of our Organisation, as we are building of the Europe of Research and Care. I am certain that our Members will be joining this important crucial event, where the future of OECI will be designed.

On behalf of all our Members and the European Cancer Community, I thank the Helsinki University Hospital Comprehensive Cancer Centre for the time and effort put towards hosting the 2024 Edition of the OECI Oncology Days.

Looking forward to seeing you in Helsinki!



Giovanni Apolone
OECI President

A handwritten signature in dark ink, which reads "Giovanni Apolone". The signature is written in a cursive style.

Director's welcome

The year 2024 marks the 46th Anniversary of the founding of the Organisation of European Cancer Institutes (OECI). Finland has been designated for the first time as the host Country for the OECI Oncology Days, and Helsinki has been awarded the privilege of welcoming the prestigious Event.

The OECI Oncology Days 2024 will take place from June 12th to June 14th in collaboration with the Helsinki University Hospital Comprehensive Cancer Centre. The Centre became a member of OECI in 2009 and was designated as a Comprehensive Cancer Centre in 2014 as the first Nordic Country. The Centre re-accredited in 2021.

The OECI46 Oncology Days cover again highly important topics in Oncology.

Special techniques in modern radiotherapy will be introduced during the 2024 Scientific Conference. New cutting-edge technology where academic research has set the basis for innovation, such as the boron neutron capture therapy (BNCT) with neutron accelerator, will be introduced. BNCT combines the targeting potential of both drugs and particles. Keeping targeting as a key topic of evolving radiotherapy techniques, we will also hear interesting keynote presentations about current evidence and future of proton therapy, MRI guided radiotherapy, and radiopharmaceuticals in molecular radiotherapy.

How to fight inequalities in cancer research and care will be the fundamental topic for the other session of the Scientific Conference. The reduction of inequalities and capacity building are among the key priorities of OECI.

During and after the Events planned during the Oncology Days, there will be time for the participants to enjoy the surroundings. Helsinki is the beautiful capital of Finland and the rapidly growing city in Europe. Helsinki was chosen as the World Design Capital for the year 2012, and in 2014 it was awarded with the City of Design status as part of the Creative Cities Network established by UNESCO.

The Oncology Days will be held at the hotel Presidentti in the very central part of Helsinki city center. 12 June is the annual Helsinki Day with many big and small events in the city. The Gala dinner will take place in the Restaurant NJK located on the island in the immediate neighbourhood of Helsinki city center and the marketplace. Welcome Reception will be hosted by the Mayor at the City Hall.

On behalf of the Helsinki University Hospital Comprehensive Cancer Centre, it is my honour and great pleasure to welcome you in Helsinki.



Johanna Mattson
HUS CCC Director

Johanna Mattson

OECI is a non-governmental, non-profit Organisation founded in Vienna in 1979, and remodelled in 2005 into OECI-EEIG - a European Economic Interest Grouping.

Today, OECI regroups more than 140 Members, which include some of the most prominent European Comprehensive Cancer Centres. Several leading cancer centres from Chile, Colombia, Jordan, Lebanon, Russian Federation, Tanzania, Turkey, Ukraine and Vietnam joined our Grouping because they believe in the importance of exchanging with – and learning from - European models of excellence.

The OECI aims to create a strong community of cancer centres and institutes by facilitating efficient partnerships and enhancing the concepts of “comprehensiveness” and “multidisciplinarity”. Our mission is to place patients at the centre of their cancer journey and to work to provide them equal access to high quality cancer care and treatments.

To achieve these goals within cancer centres, we designed the OECI A&D Programme, which is geared towards enabling a complete quality system for cancer diagnosis, care, education and research. The A&D Programme is the only cancer accreditation programme globally which evaluates comprehensive cancer care and translational research in a seamless process using OECI standards and peer review.

We strive to ensure that cancer research and innovation are fully integrated into patient care pathways by ensuring our members' active involvement in our agenda, and promoting synergies with other cancer organisations. Over the past years, we have increasingly learnt the benefits of proactively co-designing with patients the decisions related to their cancer journey. This is an important step forward, and the reason why OECI is relaunching its Collaboration for Good Practices with Patients WG, which is presently working on a new Programme of Activities, that will be launched at the OECI Oncology Days in Helsinki.

In addition, OECI dynamically works in crosscut expertise through the activities carried out by our Cancer Economics WG, Biobanks and Molecular Pathobiology WG and Outcomes Cancer Research WG, which help us further involve our Members in our agenda and foster participation in cancer-related EC projects.

Our mission to build a strong community of cancer centres closely aligns with Europe's Beating Cancer Plan and the EU Cancer Mission. The Programmes aim to ensure that by 2030, 90% of all patients should have access to National Comprehensive Cancer Centres linked through a EU Network. This is the reason why on 1 May 2023 a new Coordination and Support Action (CSA) – Comprehensive Cancer Networks for Europe (CCI4EU) - was launched under the coordination of OECI. CCI4EU brings together a large network of 27 Member States and 5 Associated Countries in a capacity building programme designed to rethink the cancer culture and reduce inequalities.


To learn more about OECI, our activities, reports and proceedings please visit the OECI website at: <http://www.oeci.eu>

The OECI Network

The OECI is a non-governmental Organisation founded in Vienna in 1979 and remodeled in 2005 into OECI-EEIG, a European Economic Interest Grouping.

OECI presently comprises 139 Members, which include some of the most prominent European Comprehensive Cancer Centres. Several major cancer centres from the Chile, Colombia, Jordan, Lebanon, Russian Federation, Tanzania, Turkey, Ukraine and Viet Nam are also members of the Organisation in order to benefit from the Accreditation and Designation Programme and to be involved in the activities promoted by the Working Groups.

The OECI aim is to accelerate the application of multidisciplinary personalised care approaches to reduce mortality and to guarantee an equitable access to care to all cancer patients.



The OECI membership

Austria

- Comprehensive Cancer Center Vienna, Vienna

Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ Kortrijk Kankercentrum AZ Groeninge, Kortrijk
- ★ Leuven Kankerinstituut (LKI), Leuven
- Oncologisch Centrum UZBrussel, Brussels
- Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels

Bulgaria

- Multiprofile Hospital for Active Treatment Heart and Brain Pleven, Pleven
- Bulgarian Joint Cancer Network (BJCN), Varna

Chile

- ★ Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago

Colombia

- Instituto Nacional de Cancerología ESE, Bogota

Croatia

- Klinika za tumore Klinički bolnički centar Sestre milosrdnice, Zagreb

Cyprus

- German Oncology Center (GOC), Limassol
- Bank of Cyprus Oncology Centre, Nicosia

Czech Republic

- ★ Masarykův onkologický ústav, Brno
- Fakultní nemocnice v Motole, Prague
- Institut biostatistiky a analýz Lékařská fakulta Masarykovy univerzity, Brno

Denmark

- ★ Vejle Sygehus, Patienternes Kræftsygehus en del af Sygehus Lillebælt, Vejle
- ★ Aarhus Universitetshospital, Aarhus
- ★ Copenhagen Comprehensive Cancer Center (CCCC) Departement of oncology Rigshospitalet, Copenhagen
- ★ Copenhagen Comprehensive Cancer Center (CCCC) Departement for cancer treatment, Herlev and Gentofte Hospital, Herlev

Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- North Estonia Medical Center, Tallinn
- AS Ida-Tallinna Keskhaigla, Tallinn

Finland

- ★ HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala, Helsinki
- ★ TYKS Syöpäkeskus Turun Yliopistollinen Sairaala, Turku
- ★ TAYS Syöpäkeskus Tampereen Yliopistollinen Sairaala, Tampere
- ★ KYS Syövänhoitokeskus Kuopion Yliopistollinen Sairaala, Kuopio
- ★ OYS Oulun Yliopistollinen Sairaala, Oulu

France

- Association Toulousaine d'Oncologie Publique (ATOP), Toulouse
- ★ Centre Léon Bérard, Lyon
- ★ Institut Curie, Paris
- ★ Institut Paoli – Calmettes, Marseille
- ★ Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse
- ★ Assistance Publique - Hôpitaux de Paris Institut Universitaire de Cancérologie APHP, Sorbonne Université, Paris

Institut du cancer Paris CARPEM

- ★ AP-HP.Centre-Université Paris Cité, Paris
- ★ Centre François Baclesse, Caen
- ★ Institut de Cancérologie de l'Ouest (ICO), Angers - Saint Herblain
- ★ Centre Henri Becquerel, Rouen
- ★ Gustave Roussy, Villejuif
- ★ ICANS Institut de cancérologie Strasbourg Europe, Strasbourg
- ★ Centre Jean Perrin, Clermont-Ferrand
- ★ Institut du Cancer de Montpellier (ICM), Montpellier
- ★ Cancer Institute AP-HP. Nord - Université Paris Cité, Paris
- ★ Centre de lutte contre le cancer Eugène Marquis, Rennes
- ★ Centre Oscar Lambret, Lille
- ★ Institut Bergonié, Bordeaux
- Institut Godinot, Reims
- Centre de Lutte Contre le Cancer Georges-François Leclerc, Dijon
- Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy
- Institut Sainte Catherine, Avignon

Germany

- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- Nationales Centrum für Tumorerkrankungen Dresden NCT/UCC, Dresden
- Charité Comprehensive Cancer Center, Berlin
- Universitäres Centrum für Tumorerkrankungen (UCT), Frankfurt
- Comprehensive Cancer Center München, Munich

Greece

- ★ General Oncology Hospital of Athens "Saint Savvas", Athens

Hungary

- ★ Országos Onkológiai Intézet, Budapest
- Országos Korányi TBC és Pulmonológiai Intézet, Budapest

Ireland

- ★ Trinity St. James's Cancer Institute, Dublin
- ★ Beaumont RCSI Cancer Centre, Dublin
- ★ Saolta University Cancer Network, Galway University Hospitals, Galway
- ★ Cork University Hospital/University College Cork, Corkú
- ★ St Vincent's UCD Cancer Centre, Dublin
- Mater Private Network, Dublin
- The Mater Misericordiae University Hospital, Dublin

Italy

- ★ Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano
- ★ IRCCS Ospedale Policlinico San Martino, Genoa
- ★ Istituto Europeo di Oncologia, Milan
- ★ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
- ★ Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale), Naples
- ★ Istituto Nazionale Tumori Regina Elena, Rome
- ★ Istituto Oncologico Veneto IRCCS-IOV, Padua
- ★ Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologia Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia

- ★ IRCCS Istituto Clinico Humanitas, Rozzano (Milan)
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Turin)
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)
- ★ IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (Verona)
- ★ Ospedale San Raffaele (OSR), Milan
- ★ Istituto Oncologico del Mediterraneo s.p.a. (IOM), Viagrande (Catania)
- ★ ASST Spedali Civili di Brescia (SCH), Brescia
- ★ Fondazione IRCCS Policlinico San Matteo, Pavia
- IFOM ETS, Milan
- IRCCS Istituto Romagnolo per lo Studio dei Tumori «Dino Amadori» - IRST s.r.l., Meldola (Forlì-Cesena)
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan
- Istituto Dermatologico San Gallicano, Rome

Jordan

- King Hussein Cancer Center, Amman

Latvia

- ★ SIA Rīgas Austrumu klīniskā universitātes slimnīca, Riga
- Paula Stradiņa Klīniskā universitātes slimnīca, Riga

Lebanon

- Naef K Basile Cancer Institute at the American University of Beirut Medical Center, Beirut

Lithuania

- ★ National Cancer Institute, Vilnius
- Vilnius University Hospital Santaros Klinikos, Vilnius

Luxembourg

- Institut National du Cancer (INC), Strassen

Moldova

- Public Health Institution Oncological Institute, Chisinau

Norway

- ★ Oslo Universitetssykehus (OUS), Oslo
- Helse Bergen HF (Haukeland University Hospital), Bergen

Poland

- Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warsaw
- Wielkopolskie Centrum Onkologii, Poznań

Portugal

- ★ Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO-Porto), Porto
- ★ Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa), Lisbon
- ★ Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO-Coimbra), Coimbra

Romania

- The "Prof. Dr. Ion Chiricută" Institute of Oncology (IOC), Cluj-Napoca
- Institutul Oncologic "Prof. Dr Alexandru Trestioreanu" Bucuresti, Bucharest

Russia Federation

- Tatarstan Cancer Center "TCC", Kazan
- N.N. Blokhin Russian Cancer Research Centre, Moscow

- National Medical Research Radiological Centre (NMRRC), Moscow

Serbia

- Oncology Institute of Vojvodina, Sremska Kamenica

Slovakia

- Biomedicinske centrum Slovenskej akademie vied, Bratislava

Slovenia

- ★ Onkolški Inštitut Ljubljana, Ljubljana

Spain

- ★ Vall d'Hebron Barcelona Campus Hospitalari, Barcelona
- ★ Fundación Instituto Valenciano de Oncología IVO, Valencia
- ★ Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat (Barcelona)
- ★ Cancer Center Clínica Universidad de Navarra, Pamplona
- ★ Institut d'Oncologia de la Catalunya Sud Hospital Universitari Sant Joan de Reus, Reus
- Centro Integral Oncológico Clara Campal, Madrid
- Fundación Jiménez Díaz University Hospital, Madrid

Sweden

- ★ Karolinska Institute and University Hospital, Stockholm
- ★ Skånes Universitetssjukhus, Lund
- ★ Sahlgrenska University Hospital, Göteborg
- ★ Uppsala University Hospital, Uppsala
- ★ Linköpings Universitetssjukhus, Linköping
- Norrlands Universitetssjukhus, Umeå

Switzerland

- Comprehensive Cancer Center Zürich (CCCZ), Zurich

Tanzania

- The Aga Khan Hospital, Dar es Salaam, Dar es Salaam

The Netherlands

- OncoZON Cancer Network, Maastricht
- ★ Netherlands Cancer Institute, Amsterdam
- ★ Maastricht University Medical Centre+, Maastricht
- ★ University Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), Groningen
- ★ Erasmus MC Cancer Institute, Rotterdam
- ★ Rijnstate, Arnhem
- IKNL Integraal Kankercentrum Nederland, Utrecht
- Radboudumc Centrum voor Oncologie, Nijmegen

Turkey

- ★ Anadolu Sağlık Merkezi, Kocaeli
- Dokuz Eylül Üniversitesi Onkoloji Enstitüsü, İzmir

Ukraine

- RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kiev

United Kingdom

- ★ The Christie NHS Foundation Trust, Manchester
- ★ Cancer Research UK Cambridge Centre, Cambridge

Viet Nam

- Bệnh viện K Viet Nam National Cancer Hospital, Hanoi

Director's foreword

HUS Comprehensive Cancer Centre (HUS CCC) combines expertise in several specialties and its clinicians are actively involved in clinical and translational research. The patient is at the core of all operations, and delivering top quality and safe treatment as well as enabling access to novel treatments in clinical trials is the centre's foremost task. The Centre is strongly committed to improving quality of care and treatment results, and the objective is to maintain its position among the leading cancer centres in Europe. This requires constant cooperation with international networks, such as OECI.

Description of the Centre and history

The first department of radiotherapy started its activities in Helsinki in 1936 and since then the unit has continuously grown to become the first Nordic and second European CCC within the OECI network in 2014. HUS CCC is responsible for the oncological treatment of cancer throughout the area of Helsinki and Uusimaa, with a population of approximately 1.7 million. It is Finland's largest Cancer Centre and one of the largest in the Nordic Countries. It has overall responsibility for the treatment of cancer patients, integrating the oncological treatment of all cancer types including haematology and breast surgery. Each year, CCC treats over 30 000 patients, of whom more than 10 000 are new patients. The Centre employs 600 health care professionals, more than 130 of whom are physicians.

Main research activities

The Centre supports clinical and translational cancer research on a wide scale from first-in-man and early phase I studies to large Phase III and IV trials, and range from surgical oncology, radiation therapy, medical oncology and haematology to palliative care and research on psychosocial aspects of cancer. The scientists of CCC coordinate and take part in national and international clinical trials. All open studies for patients are available on the Centre's web site. HUS CCC has one of the first global hospital-based neutron accelerators for BNCT (boron neutron capture therapy).

Core Facilities

Medical research and care in Helsinki take place under the umbrella of the Academic Medical Centre Helsinki (AMCH), which consists of the HUS and the University of Helsinki. The AMCH provides a comprehensive collection of core services from biobanking to genomics, metabolomics, proteomics, bioinformatics, imaging, molecular pathology and data lakes. Systems medicine approach has been built for preclinical drug research, predictive biomarker discovery and novel personalized medicine clinical trials. Besides haematological cancers the systems precision medicine approach has been expanded to include lymphomas and solid tumours using innovative organoid and cancer-on-a-chip technologies.

Education

As a university level teaching hospital, HUS CCC is responsible for the teaching of medical students, specialist training for clinical haematology, medical oncology and radiotherapy and for the training of graduate students in the fields of clinical and translational oncology and haematology. The Centre also functions as a training unit for the sub-specialty in breast surgery and palliative medicine. In addition, the Centre educates hospital physicists, nursing students, and a formal cancer nurse education program has also been developed in collaboration with the Helsinki Metropolia University of applied Sciences.

HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala

P.O. Box 180
(Haartmaninkatu 4)
FI-00029 HUS Helsinki
Finland

Director:
Adjunct Professor **Johanna Mattson**
Head of Hematology:
MD, PhD **Aino Lepäntalo**
Head of Solid Tumors:
Adjunct Professor **Micaela Hernberg**
Head of Radiotherapy:
Professor **Mikko Tenhunen**
Head of Breast Surgery:
Adjunct Professor **Tuomo Meretoja**
Head of Palliative Care Center:
Professor **Tiina Saarto**
Research Director:
Professor **Peeter Karihtala**
Chief Nursing Officer:
RN, MHS, MBA **Vuokko Kolhonen**
Quality Manager:
RN, MNsc. **Frans Åkerblom**
OECI Contact Person:
Assistant **Sanna-Leena Pessa**



Oncology Days Helsinki - Timetable

Oncology Days Helsinki - Timetable

	11 June 2024	12 June 2024	
MORNING	A&D Board meeting 11.00 – 13.00 <i>Restricted to A&D Board Members</i>	Accreditation & Designation Session 1 08.45 – 10.45 Coffee Break 10.45 – 11.00 Accreditation & Designation Session 2 11.00 – 13.00	
	Lunch	Lunch	
AFTERNOON	OECI Board & Extended Board Meeting 14.00 – 18.00 <i>Restricted to OECI Board and Extended Board Members</i>	Collaboration for Good Practices with Patients WG Session 14.00 – 16.00	Cancer Economics WG Session 14.00 – 16.00 Costs, cost-effectiveness and consequences of cancer treatment
		Coffee Break	
		Biobanks and Molecular Pathobiology WG Session 16.30 – 18.30 Biobanks and pathobiology in the era of personalized cancer care: promises and challenges	Outcomes Cancer Research WG Session 16.30 – 18.30 The use of patient PREMs for performance measurement and quality improvement in oncology care
EVENING	Board Dinner	Gala Dinner Marine style restaurant NJK 20.00 -22.00	

	13 June 2024	14 June 2024	
MORNING	Scientific Conference Session 1 08.45 – 10.45 Special techniques in radiotherapy	General Assembly Administrative Session & Ceremony A&D Certificates 08.30 – 10.00 <i>Restricted to OECI Member Legal Representatives or their Delegates</i>	MORNING
	Coffee Break 10.45 – 11.00	Coffee Break 10.00 – 10.15	
	Scientific Conference Session 2 11.00 – 13.00 How to fight inequalities in cancer research and care	Open discussion with Members & Close of the 2024 General Assembly 10.15 – 12.30 <i>Restricted to OECI Member Legal Representatives or their Delegates</i>	
	Lunch	Lunch	
AFTERNOON	EBCP Session <i>Alignment and synergies among the most relevant European Joint Actions CraNE2 and JANE2</i> 14.00 – 15.30		AFTERNOON
	Coffee Break		
	CCI4EU - CSA Session <i>Comprehensive Cancer Infrastructures for the European Union</i> 16.00 – 16.45		
	Quality of Life in Oncology: the EUonQoL Pilot Study 16.45 – 17.30		
EVENING	Welcome Reception City Hall at 18.00 - 19.45 Concert at the Tempelliakio rock Church 20.00 - 20.45		EVENING

Accreditation and Designation Session 1

The Quality and Accreditation sessions will focus on the importance of Comprehensive Cancer Networks and their accreditation, and give some examples from around Europe. They will also focus on capacity building in Comprehensive Cancer Infrastructures with an example of a project recently completed in an EU country. New and developments in the Accreditation programme will be described, including the standards revision process. Finally, there will be a panel of Cancer Centre directors answering questions on main quality issues facing Cancer Centres today, and how OECl can help.

June 12th

08.45 - 10.45

Hotel Presidentti

- 08.45 **News and changes in A&D**
Simon Oberst and Jean-Benoît Burrion (20 minutes plus Q&A)
- 09.15 **How the accreditation process helps us improve**
Instituto Oncológico Fundación Arturo López Pérez – Cristian Ayala Munita (15')
IRCCS Sacro Cuore don Calabria di Negrar – Stefania Gori (15')
Beaumont RCSI, Dublin – Leonie Young (15')
- 09.45 **The importance of Comprehensive Cancer Networks**
Simon Oberst (15')
- 10.00 **ONCOZON – our experience of OECl accreditation**
Fabrizia Ketelaars (15')
- 10.15 **FICAN – a national cancer network**
Tommi Mäkelä (15')
- 10.30 **Q&A**
- 10.45 **Coffee Break**

Accreditation and Designation Session 2

- 11.00 **The ICCCS Project – a Roadmap towards a Comprehensive Cancer Infrastructure in Latvia**
The Capacity Building approach – Mef Nilbert (15')
Progress and impact in Latvia – Speaker tbc (15')
Q&A (15')
- 11.45 **Oncology Nursing in Finland: Empowering cancer nurses' knowledge and professional growth**
Aino Kormilainen
- 12.00 **Directors' Panel: What are the main quality issues facing Cancer Centres today, and how can OECl help?**
How can the A&D Programme add value to centres in re-accreditation?
Chairperson: Simon Oberst
- Josep Taberner, Vall D'Hebron Barcelona Campus, Barcelona, Spain
- Frédéric Penault-Llorca, Centre Jean Perrin, Clermont-Ferrand, France
- Gennaro Ciliberto, Regina Elena, Rome, Italy
- Lenne-Triin Kõrgvee, Sihtasutus Tartu Ülikooli Kliinikum, Tartu, Estonia
- Johanna Mattson, HUS Helsinki University Hospital, Helsinki, Finland
- John Kennedy, Trinity St. James's Cancer Institute, Dublin, Ireland
- 13.00 **Lunch**

June 12th

11.00 - 13.00

Hotel Presidentti

Collaboration for Good Practices with Patients WG Session

- 14.00 **Enhancing patient involvement: OECl for patients, with patients**
- Welcome**
Giovanni Apolone (2')
- Collaboration between cancer centres and cancer patients' organisations: the Patients WG Draft Proposal**
Delia Nicoară (10')
- Feedback on WG on Patients document**
Francesco De Lorenzo (10')
- Introduction and results of OECl Cancer Centres' Survey**
Paulina Bravo and Francesco De Lorenzo (15')
- Cancer survivors' perspective**
Alexandre Brutti (10')
- Discussion**
- Proposal of the WG Chairperson and conclusion**
Claudio Lombardo

June 12th

14.00 - 16.00

Hotel Presidentti

Cancer Economics WG Session

June 12th

14.00 - 16.00

Hotel Presidentti

In the session organized by the Cancer Economics Working group we start with a presentation of a comparative study presenting the savings through national agreements on drug access and coverage, on national level in at least 10 EU countries. In some we can present resulting price levels.

Further, the developments in data management of electronic patient records in hospitals to generate real world data that can be used for effectiveness research and health technology assessment will be shown using two case studies from the OncoValue project.

As early detection is becoming increasingly important, the economic consequences and demands for coverage decisions will further be elaborated using a case study concerning oral cancer early detection strategies.

Lastly, the TaskForce on SocioEconomic Consequences has succeeded in publishing it's consensus statement on definitions and research challenges in Lancet Oncology recently. We will use this session to further build on this success in presenting some latest findings and a research agenda for the coming years.

Cost-effectiveness and consequences of cancer treatment

Chairperson: *Wim H. van Harten*

Welcome

Wim H. van Harten (10')

Transparency of cancer medicine prices and - rebates

Sabine Vogler and Nora Franzen (30')

Oncovalue: Using Real World Data for Real World based Technology Assessment

Kevin Tittel and Zainab Al-Khayat (20')

Oncovalue-case study

Johanna Mattson (20')

Health Technology Assessment of early detection for oral cancer

Lionel Perrier and Valesca Retèl (20')

OECD Task Force Socio-Economic Impact: state of the art and progress

Michael Schlander (15')

Closing

Wim H. van Harten (5')

Biobanks and Molecular Pathobiology WG Session

June 12th

16.30 - 18.30

Hotel Presidentti

The Pathobiology and Biobanks session focuses on issues that are developing rapidly and crucial for translational and clinical cancer research in the near future. These include the role of biobanks in the era of precision medicine, developments in digital pathology, organization and implementation of research databases (in the EHDS era), and molecular pathology training and quality issues.

Biobanks and pathobiology in the era of personalized cancer care: promises and challenges

Chairpersons: *Johanna Arola and Olli Carpén*

Biobanks – bridging research and precision cancer therapy

Kimmo Porkka (25'+5')

Bigpicture – a digital image repository to advance AI in pathology

Anna Bodén (25'+5')

How to collect, manage, and utilize large data repositories to foster medical research in a sustainable way

Tommi Nyrönen (25'+5')

European masters program in molecular pathology

Marius Illié (25'+5')

Cancer Outcomes Research WG Session

June 12th

16.30 - 18.30

Hotel Presidentti

Patient reported experience measures (PREMs) are survey tools used to record patient perceptions about various elements of the healthcare. PREMs are increasingly mandated for use in national and international health system performance comparisons, including in public reporting, developing provider payment models and identifying service or ward level improvement actions. Despite current developments and international initiatives, barriers exist to their widespread use.

The use of patient PREMs for performance measurement and quality improvement in oncology care

Chairpersons: *Cinzia Brunelli and Jean-Benoît Burrión*

Satisfaction vs experience: how and why measure patient perception of health care

Sabina De Rosis

Current use of PREMs in oncology care in EU and their actionability

Christoph Kowalski

Routine collection of PREMs in cancer care: is it feasible?

Olatz Garin Boronat

Experience of participatory research in PREMs assessment

Nanne Bos

Scientific Conference Session 1

June 13th

08.45 - 10.45

Hotel Presidentti

Special techniques in modern radiotherapy with targeting as a key topic will be introduced. Keynote presentations are given about current evidence and future of boron neutron capture therapy (BNCT), proton therapy, MRI guided radiotherapy, and radiopharmaceuticals in molecular radiotherapy.

Special techniques in radiotherapy

Chairpersons: *Mikko Tenhunen and Johanna Mattson*

The rationale, clinical results and future development of BNCT (Boron Neutron Capture Therapy)

Heikki Joensuu (30' with discussion)

Proton therapy: present evidence and future

Cai Grau (30' with discussion)

Clinical applications of MR linac in radiotherapy

Anna Bruynzeel (30' with discussion)

Radiopharmaceuticals in modern cancer therapy

Karolien Goffin (30' with discussion)

Coffee Break

June 13th

11.00 - 13.00

Hotel Presidentti

Scientific Conference Session 2

How to fight inequalities in cancer research and care

Chairpersons: *Iwona Lugowska and Johanna Mattson*

Cancer Care Beacon Project:

Reducing disparities across the European Union

Roberto Grasso

Policy Advocacy and Healthcare Reform: A Roadmap to Reducing Cancer Inequalities in Europe

Marek Svoboda

Innovative Approaches to Promote Equity in Cancer Research Funding Across European Regions

Péter Nagy

Unlock the potential of real-world data of rare solid cancers of adults: the EURACAN data ecosystem to reduce disparities in cancer

Annalisa Trama

Economic Empowerment for Patient-Centric Care: Reducing Financial Barriers in Cancer Research

Wim H. van Harten

EBCP Session

This session will outline the main objectives and deliverables of CraNE2 and JANE2, and it will explore their implications in an interactive session with the audience, looking for synergies.

June 13th

14.00 - 15.30

Hotel Presidentti

Alignment and synergies among the most relevant European Joint Actions CraNE2 and JANE2

Chairpersons: Thierry Philip and Iwona Lugowska

From JANE1 to JANE2: a role for OECI?

Paolo Casali

From CraNE1 to CraNE2 (EUNetCCC): the European Network of CCC

Per Magnus Mæhle

Discussion

CCI4EU - CSA Session Comprehensive Cancer Infrastructures for the European Union

This session will explain the main objectives and deliverables of the project, which aims to test strategies to build capacity in research and innovation in cancer in Comprehensive Cancer Infrastructures throughout the EU.

June 13th

16.00 - 16.45

Hotel Presidentti

Alignment and synergies among the most Capacity Building interventions

Giovanni Apolone

Overview of CCI4EU

Simon Oberst

Introducing the Maturity Model

Eva Jolly

Quality of Life in Oncology: the EUonQoL Pilot Study

The project pilot survey aims to validate the EUonQoL kit, a new quality of life assessment tool. The survey will be carried out in the second half of 2024 through a large collaborative network of OECI oncology centers.

June 13th

16.45 - 17.30

Hotel Presidentti

Chairpersons: Giovanni Apolone and Cinzia Brunelli

16.45 EUonQoL project overview

Cinzia Brunelli

16.50 The pilot survey protocol

Luana Caselli

17.05 Participating centres

Claudio Lombardo

17.10 Pilot survey co-design

Nanne Bos, Laura Pinnavaia and Inke Minnée-van Braak

17.20 Q&A

General Assembly Administrative Session & Ceremony A&D Certificates



June 14th

08.00 - 10.45

Hotel Presidentti

08.00 **Registration**

08.15 **Opening**

General Assembly Constitution, welcome and approval of the Agenda
Giovanni Apolone

08.30 **Administrative Session**

Chairperson: Giovanni Apolone

Point 1: Approval of the General Assembly Minutes of 17th June 2023

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

Giovanni Apolone

Point 2: Approval of the Financial Statement 2023 and discharge to the Board

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

Diego Pazienza

Point 3: OECI 2024 Provisional Budget

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

Claudio Lombardo

Point 4: OECI Board composition for the coming years and appointment of new WG Chairpersons

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented, only for the nomination of new Board Members)

Giovanni Apolone

Point 5: Proposal of modification of Article 6.2 of the OECI Statute - Associate Members Type C

(vote requested: decision to be taken by simple majority of the OECI Full Members present or represented)

Giovanni Apolone

Point 6: New applications to the OECI membership and requests of exemption from membership fee payment

(vote requested: for full membership and fee exemption - decision to be taken by unanimity of the OECI Full Members present or represented; for associate membership – decision to be taken by simple majority of the OECI Full Members present or represented)

Claudio Lombardo

Point 6: Oncology Days 2025, and for the coming years

Giovanni Apolone and Olga Balaoura

10.45 *Coffee Break*

CEREMONY FOR THE DELIVERY OF THE OECI A&D CERTIFICATES June 2023-June 2024

Giovanni Apolone and Jean-Benoît Burrión

OncoZON Cancer Network

Maastricht, The Netherlands

IRCCS Istituto Clinico Humanitas

Milan, Italy

Centre Léon Bérard

Lyon, France

Centre Henri Becquerel

Rouen, France

National Institute of Oncology (NIO)

Budapest, Hungary

National Cancer Institute

Vilnius, Lithuania

Instituto Oncológico Fundación Arturo López Pérez (FALP)

Providencia (Santiago), Chile

Kortrijk Cancer Centre AZ Groeninge

Kortrijk, Belgium

Ospedale Policlinico San Martino IRCCS

Genoa, Italy

Open discussion with Members & Close of the 2024 General Assembly

June 14th

11.00 - 13.00

Hotel Presidentti

11.00 **OECI strategy for the incoming years**

Chairperson: Giovanni Apolone

11.20 **Extra European Affairs: the OECIWORLD Network**

Thierry Philip

11.30 **Open discussion with the Members**

Chairpersons: Giovanni Apolone and Iwona Lugowska

12.45 **Closure of the 2024 OECI General Assembly**

13.00 *Lunch*

Invited speakers

Zainab Al-Khayat
Amsterdam, The Netherlands

Jean-Benoît Burrión
Bruxelles, Belgium

Stefania Gori
Verona, Italy

Christoph Kowalski
Berlin, Germany

Delia Nicoară
Cluj, Romania

Michael Schlander
Heidelberg, Germany

Giovanni Apolone
Milan, Italy

Olli Carpén
Helsinki, Finland

Roberto Grasso
Milan, Italy

Claudio Lombardo
Brussels, Belgium

Tommi Nyrönen
Helsinki, Finland

Marek Svoboda
Brno, Czech Republic

Johanna Arola
Helsinki, Finland

Paolo Casali
Milan, Italy

Cai Grau
Aarhus, Denmark

Iwona Lugowska
Warsaw, Poland

Simon Oberst
Bornholm, Denmark

Josep Taberneró
Barcelona, Spain

Olga Balaoura
Athens, Greece

Luana Caselli
Milan, Italy

Marius Illé
Nice, France

Per Magnus Mæhle
Oslo, Norway

Diego Paziienza
Brussels, Belgium

Mikko Tenhunen
Helsinki, Finland

Anna Bodén
Linköping, Sweden

Gennaro Ciliberto
Rome, Italy

Heikki Joensuu
Helsinki, Finland

Tomi Mäkelä
Helsinki, Finland

Frédérique Penault-Llorca
Clermont-Ferrand, France

Kevin Tittel
Amsterdam, The Netherlands

Nanne Bos
Utrecht, The Netherlands

Francesco De Lorenzo
Rome, Italy

Eva Jolly
Stockholm, Sweden

Johanna Mattson
Helsinki, Finland

Lionel Perrier
Lyon, France

Annalisa Trama
Milan, Italy

Paulina Bravo
Santiago, Chile

Sabina De Rosi
Pisa, Italy

John Kennedy
Dublin, Ireland

Inke Minnée-van Braak
The Hague, The Netherlands

Thierry Philip
Paris, France

Wim H. van Harten
Amsterdam, The Netherlands

Cinzia Brunelli
Milan, Italy

Nora Franzen
Amsterdam, The Netherlands

Fabrizia Ketelaars
Maastricht, The Netherlands

Cristian Ayala Munita
Santiago, Chile

Laura Pinnavaia
Milan, Italy

Sabine Vogler
Vienna, Austria

Alexandre Brutti
Paris, France

Olatz Garin Boronat
Barcelona, Spain

Lenne-Triin Kõrgvee
Tartu, Estonia

Péter Nagy
Budapest, Hungary

Kimmo Porkka
Helsinki, Finland

Leonie Young
Dublin, Ireland

Ame Bruynzeel
Amsterdam, The Netherlands

Karolien Goffin
Leuven, Belgium

Aino Kormilainen
Helsinki, Finland

Mef Nilbert
Lund, Sweden

Valesca Retèl
Amsterdam, The Netherlands





Organisation
of European
Cancer Institutes
European Economic
Interest Grouping



Oncology Days

11-14 June 2025 Athens, Greece

GENERAL ASSEMBLY AND
SCIENTIFIC CONFERENCES

In collaboration with:



DEVELOPING
THE FUTURE IN
COMPREHENSIVE
CANCER CARE

The OECI Board



President and Chairperson
OECI EU Affairs
Giovanni Apolone
Italy



Past President
Thierry Philip
France



Executive Secretary
Iwona Lugowska
Poland



Treasurer
Manuel Llombart Fuertes
Spain



Elected Member
Christian Brandts
Germany



Elected Member
Maja Čemažar
Slovenia



Elected Member
József Lövey
Hungary



Elected Member Chairperson
OECI Gender Equality
Jacqueline Stouthard
The Netherlands

Co-opted Members to the OECI Board



OECI General Manager
Claudio Lombardo
Belgium - Italy

Accreditation and Designation Programme



A&D Board Chairperson
Jean-Benoît Burrión
Belgium



A&D Quality Director
Simon Oberst
Denmark

Working Groups



**Biobanks and Molecular
Pathobiology WG Chairperson**
Giorgio Stanta
Trieste, Italy



**Cancer Outcomes Research
WG Chairperson**
Cinzia Brunelli
Milan, Italy



**Cancer Economics
WG Chairperson**
Wim H. van Harten
Amsterdam, The Netherlands



**Collaboration for Good
Practices with Patients
WG Chairperson**
Pending

OECI-EEIG Brussels Office - c/o Fondation Universitaire - 11, Rue d'Egmont
Phone: +32 2 512 0146, B-1000 Brussels, Belgium
www.oeci.eu oeci@oeci.eu



THE OEI 2024 INTERNATIONAL SCIENTIFIC COMMITTEE

Presidents

Giovanni Apolone and Johanna Mattson

Members

Giovanni Apolone, Christian Brandts, Jean-Benoît Burrión,
Maja Čemažar, Cinzia Brunelli, Olli Carpén, Manuel Llombart Fuertes,
Claudio Lombardo, József Lövey, Iwona Lugowska, Peeter Karihtala,
Johanna Mattson, Simon Oberst, Giorgio Stanta, Wim H. van Harten,
Jacqueline M.L. Stouthard, Mikko Tenhunen

THE OEI 2024 ONCOLOGY DAYS SECRETARIATS

GENOA: Daniela Garbarino, Patrizia Sommella, Diana Kocheharova

BRUSSELS: Roxana Plesoianu

MILAN: Eleonora De Palo

HELSINKI: Sanna-Leena Pessa, Karoliina Koski

OEI 2024 ONCOLOGY DAYS COORDINATING OFFICE

Claudio Lombardo

Phone +32 2 512 01 46

oei@oei.eu - www.oei.eu

In collaboration with:



Comprehensive Cancer Centre

Supported by:

